Systemic Drug Delivery Strategies: Delivery Strategies and Engineering Technologies in Cancer Immunotherapy, Volume 2 examines the challenges of delivering immuno-oncology therapies, focusing specifically on the multiple technologies of affective drug delivery strategies. Immuno-oncology (IO) is a growing field of medicine at the interface of immunology and cancer biology leading to development of novel therapeutic approaches, such as chimeric antigen receptor T-cell (CAR-T) and immune checkpoint blockade antibodies, that are clinically approved approaches for cancer therapy. Although currently approved IO approaches have shown tremendous promise for select types of cancers, broad application of IO strategies could even further improve the clinical success, especially for diseases such as pancreatic cancer, brain tumors where the success of IO so far has been limited. This volume of Delivery Strategies and Engineering Technologies in Cancer Immunotherapy discusses methods of targeting tumors, CRISPR technology, and vaccine delivery among many other delivery strategies.
Systemic Drug Delivery Strategies: Delivery Strategies and Engineering Technologies in Cancer Immunotherapy, Volume 2 creates a comprehensive treaty that engages the scientific and medical community who are involved in the challenges of immunology, cancer biology, and therapeutics with possible solutions from the nanotechnology and drug delivery side.
1. Systemic Drug Delivery Strategies - p. Page i 2. Cover - p. Page i 3. Front Matter - p. Page ii 4. Table of Contents - p. Page iii 5. Copyright - p. Page iv 6. Dedication - p. Page v 7. Contributors - p. Page v 8. Preface - p. Page ix 9. Acknowledgments - p. Page xi 10. List of Illustrations - p. Page xii 11. List of Tables - p. Page xiii 12. Chapter One : Delivery strategies for immune checkpoint blockade - p. Page xiii 13. Chapter Two : Delivery strategies for ex vivo and in vivo T-cell reprogramming - p. Page 24 14. Chapter Three : Targeting natural killer cells in cancer immunotherapy - p. Page 54 15. Chapter Four : Delivery strategies for reprogramming tumor-associated macrophages - p. Page 76 16. Chapter Five : Delivery strategies of RNA therapeutics for ex vivo and in vivo B-cell malignancies - p. Page 109 17. Chapter Six : Targeting tumor-associated neutrophils in immunotherapy - p. Page 141 18. Chapter Seven : Targeting cancer-associated fibroblasts in immunotherapy - p. Page 157 19. Chapter Eight : Oncolytic viral particle delivery - p. Page 201 20. Chapter Nine : Extracellular vesicles in tumor immunotherapy - p. Page 226 21. Chapter Ten : Nonviral gene editing in cancer immunotherapy - p. Page 248 22. Chapter Eleven : Nucleic acid-based immune checkpoint blockade: Progress and potential - p. Page 270 23. Chapter Twelve : Local and systemic delivery strategies for glioma immunotherapy - p. Page 290 24. Chapter Thirteen : Delivery strategies for STING agonists - p. Page 327 25. Chapter Fourteen : Delivery strategies for cancer vaccines and immunoadjuvants - p. Page 352 26. Chapter Fifteen : Targeted delivery and reprogramming of myeloid-derived suppressor cells (MDSCs) in cancer - p. Page 398 27. Chapter Sixteen : Delivery of radioimmunotherapy for solid tumors - p. Page 425 28. Chapter Seventeen : Targeted photodynamic immunotherapy - p. Page 452 29. Chapter Eighteen : Local immunotherapy of cancer and metastasis - p. Page 477 30. Chapter Nineteen : Delivery strategies to overcome tumor immunotherapy resistance - p. Page 519 31. Index - p. Page 541
Systemic Drug Delivery Strategies: Delivery Strategies and Engineering Technologies in Cancer Immunotherapy, Volume 2 examines the challenges of delivering immuno-oncology therapies, focusing specifically on the multiple technologies of affective drug delivery strategies. Immuno-oncology (IO) is a growing field of medicine at the interface of immunology and cancer biology leading to development of novel therapeutic approaches, such as chimeric antigen receptor T-cell (CAR-T) and immune checkpoint blockade antibodies, that are clinically approved approaches for cancer therapy. Although currently approved IO approaches have shown tremendous promise for select types of cancers, broad application of IO strategies could even further improve the clinical success, especially for diseases such as pancreatic cancer, brain tumors where the success of IO so far has been limited. This volume of Delivery Strategies and Engineering Technologies in Cancer Immunotherapy discusses methods of targeting tumors, CRISPR technology, and vaccine delivery among many other delivery strategies.
Systemic Drug Delivery Strategies: Delivery Strategies and Engineering Technologies in Cancer Immunotherapy, Volume 2 creates a comprehensive treaty that engages the scientific and medical community who are involved in the challenges of immunology, cancer biology, and therapeutics with possible solutions from the nanotechnology and drug delivery side.
1. Systemic Drug Delivery Strategies - p. Page i 2. Cover - p. Page i 3. Front Matter - p. Page ii 4. Table of Contents - p. Page iii 5. Copyright - p. Page iv 6. Dedication - p. Page v 7. Contributors - p. Page v 8. Preface - p. Page ix 9. Acknowledgments - p. Page xi 10. List of Illustrations - p. Page xii 11. List of Tables - p. Page xiii 12. Chapter One : Delivery strategies for immune checkpoint blockade - p. Page xiii 13. Chapter Two : Delivery strategies for ex vivo and in vivo T-cell reprogramming - p. Page 24 14. Chapter Three : Targeting natural killer cells in cancer immunotherapy - p. Page 54 15. Chapter Four : Delivery strategies for reprogramming tumor-associated macrophages - p. Page 76 16. Chapter Five : Delivery strategies of RNA therapeutics for ex vivo and in vivo B-cell malignancies - p. Page 109 17. Chapter Six : Targeting tumor-associated neutrophils in immunotherapy - p. Page 141 18. Chapter Seven : Targeting cancer-associated fibroblasts in immunotherapy - p. Page 157 19. Chapter Eight : Oncolytic viral particle delivery - p. Page 201 20. Chapter Nine : Extracellular vesicles in tumor immunotherapy - p. Page 226 21. Chapter Ten : Nonviral gene editing in cancer immunotherapy - p. Page 248 22. Chapter Eleven : Nucleic acid-based immune checkpoint blockade: Progress and potential - p. Page 270 23. Chapter Twelve : Local and systemic delivery strategies for glioma immunotherapy - p. Page 290 24. Chapter Thirteen : Delivery strategies for STING agonists - p. Page 327 25. Chapter Fourteen : Delivery strategies for cancer vaccines and immunoadjuvants - p. Page 352 26. Chapter Fifteen : Targeted delivery and reprogramming of myeloid-derived suppressor cells (MDSCs) in cancer - p. Page 398 27. Chapter Sixteen : Delivery of radioimmunotherapy for solid tumors - p. Page 425 28. Chapter Seventeen : Targeted photodynamic immunotherapy - p. Page 452 29. Chapter Eighteen : Local immunotherapy of cancer and metastasis - p. Page 477 30. Chapter Nineteen : Delivery strategies to overcome tumor immunotherapy resistance - p. Page 519 31. Index - p. Page 541
